Literature DB >> 29075057

Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients.

Hadeer A Abbassy1, Reham A Aboelwafa1, Omar M Ghallab2.   

Abstract

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that has a highly variable clinical course. Genomic features as zeta-chain-associated protein kinase 70 (ZAP70) expression and CD38 expression provide further differentiation of disease prognosis. Extensive studies have confirmed the oncogenic activities of IL-9 in lymphoma. The aim of the current study was to investigate the contribution of IL-9 expression to the pathogenesis of CLL and its correlation to other prognostic parameters. This study was conducted on 80 patients at diagnosis with CLL and 80 healthy controls. Using real time polymerase chain reaction and enzyme linked immunosorbant assay, IL-9 mRNA expression and its serum level were compared between patients and controls. They were both correlated with other prognostic factors.
RESULTS: There was an overexpression of IL-9 in CLL patients that correlated with modified Rai staging, ZAP70, CD38 and all hallmarks of an active and aggressive disease. The correlation between IL-9 upregulation and patient characteristics provided direct clinical evidence for its contribution to the pathogenesis of CLL. In conclusion, significantly higher expression of IL-9 measured at both the mRNA and the protein levels in patients with CLL that correlates with more complex course of the disease and worse prognosis may allow one to speculate its importance in the pathogenesis of the disease and its possible impact on prognosis.

Entities:  

Keywords:  CLL; Egyptian patients; Expression; Interleukin-9; Therapeutic target

Year:  2017        PMID: 29075057      PMCID: PMC5640552          DOI: 10.1007/s12288-017-0804-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  28 in total

1.  Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.

Authors:  Matthias Ritgen; Alexandra Lange; Stephan Stilgenbauer; Hartmut Dohner; Christian Bretscher; Heidi Bosse; Ariane Stuhr; Michael Kneba; Peter Dreger
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 3.  Innate lymphoid cells: new paradigm in immunology of inflammation.

Authors:  Vijay Kumar
Journal:  Immunol Lett       Date:  2013-11-11       Impact factor: 3.685

4.  Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.

Authors:  Femke Van Bockstaele; Valerie Pede; Ann Janssens; Filip Callewaert; Fritz Offner; Bruno Verhasselt; Jan Philippé
Journal:  Clin Chem       Date:  2006-12-07       Impact factor: 8.327

5.  Role of high expression of IL-9 in prognosis of CLL.

Authors:  Na Chen; Xiao Lv; Peipei Li; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 6.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

7.  Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice.

Authors:  Yi Shang; Shizuko Kakinuma; Yoshiko Amasaki; Mayumi Nishimura; Yoshiro Kobayashi; Yoshiya Shimada
Journal:  In Vivo       Date:  2008 Nov-Dec       Impact factor: 2.155

8.  Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.

Authors:  M Fischer; M Bijman; D Molin; F Cormont; C Uyttenhove; J van Snick; C Sundström; G Enblad; G Nilsson
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Authors:  Tekla Hornakova; Judith Staerk; Yohan Royer; Elisabetta Flex; Marco Tartaglia; Stefan N Constantinescu; Laurent Knoops; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

10.  Overexpression of IL-9 receptor in diffuse large B-cell lymphoma.

Authors:  Xiao Lv; Lili Feng; Xiaosheng Fang; Yujie Jiang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15
View more
  1 in total

Review 1.  Interleukin (IL)-9 Supports the Tumor-Promoting Environment of Chronic Lymphocytic Leukemia.

Authors:  Laura Patrussi; Nagaja Capitani; Cosima T Baldari
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.